Firesorb生物可吸收支架治疗冠心病的首次人体研究四年结果
FUTURE I研究为前瞻性、单中心、非盲法首次人体试验,纳入45例单支单处原发冠状动脉狭窄病变患者,成功置入Firesorb生物可吸收支架后按2∶1随机分为队列1(n=30)和队列2(n=15)。4年随访显示部分患者支架完全降解吸收,无靶病变失败及支架内血栓事件,患者相关临床复合终点发生2例(4.4%)。
要点
- 4年随访无靶病变失败和支架内血栓事件。
- 部分患者4年时支架已完全降解吸收,未见支架贴壁不良。
- 患者相关临床复合终点发生2例(4.4%)。
核心结论
- 置入Firesorb支架术后4年时部分患者可出现支架完全降解吸收。
- Firesorb支架治疗简单冠状动脉病变安全、有效。
研究设计与样本
- FUTURE I研究为前瞻性、单中心、非盲法首次人体试验,评估Firesorb支架治疗冠状动脉狭窄病变的可行性、初步安全性和有效性。
- 2016年1至3月在阜外医院入选原发、原位、单支、单处冠状动脉狭窄病变患者45例,成功置入支架后以2∶1随机分为队列1(n=30)和队列2(n=15)。
主要发现
- 45例患者年龄(54.4±9.3)岁,男性35例(77.8%)。
- 4年时队列1中10例复查冠状动脉造影及OCT,其中2例支架完全降解吸收,其他8例与队列2患者3年时OCT比较支架降解程度增加,未见支架贴壁不良。
- 4年临床随访率100%,2例发生患者相关临床复合终点(4.4%)。
- 4年随访期间无靶病变失败、明确或可能的支架内血栓事件。
关键数值与推荐
- 主要终点为靶病变失败(TLF),包括心原性死亡、靶血管心肌梗死、缺血驱动的靶病变血运重建。
- 次要终点为患者相关临床复合终点(PoCE),包括全因死亡、所有心肌梗死、所有血运重建事件。
临床怎么用
- Firesorb支架可用于简单冠状动脉病变的治疗,4年随访显示安全有效。
- 术后4年部分患者支架可完全降解吸收,未见支架贴壁不良。
局限性
- 本研究为单中心、非盲法、首次人体试验,样本量45例。
- 4年时仅队列1中10例患者复查了冠状动脉造影及OCT检查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the 4-year clinical outcomes of patients following Firesorb bioresorbable scaffold (BRS) implantation. Methods: The study reported the 4-year follow-up results of the FUTURE I study. FUTURE I was a prospective, single-center, open-label, first-in-man study which evaluated the feasibility, preliminary safety, and efficacy of Firesorb stent in the treatment of coronary artery stenosis. A total of 45 patients with single de novo lesions in native coronary arteries ,who hospitalized in Fuwai Hospital from January to March 2016 were enrolled. After successfully stent implantation these patients were randomized in a 2∶1 ratio into cohort 1 (n=30) or cohort 2 (n=15). The patients in cohort 1 underwent angiographic, IVUS or OCT examination at 6 months and 2 years; and cohort 2 underwent angiographic, IVUS or OCT at 1 and 3 years. All patients underwent clinical follow-up at 1, 6 months and 1 year and annually thereafter up to 5 years. The primary endpoint was target lesion failure (TLF, including cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization). Secondary endpoints included patient-oriented composite endpoint (PoCE, defined as composite of all death, all miocardial infarction, or any revascularization). Results: A total of 45 patients were enrolled and implanted with Firesorb BRS, including 35 males (77.8%), and the age was (54.4±9.3) years. At 4 years, 10 patients in cohort 1 were reexamined by coronary angiography and OCT examination. Among them, 2 patients' stents were completely degraded and absorbed. Compared with the OCT images of the other 8 patients in cohort 2 at 3 years, the degree of stent degradation was increased, and no stent adherence was found. The 4-year clinical follow-up rate was 100%. In 4-year clinical following up, 2 patients suffered PoCE (4.4%): 1 patient underwent non-target vessel revascularization the day after index procedure and target vessel revascularization (Non-target lesion revascularization) at 2-year imaging follow-up; the other patient underwent target lesion revascularization during imaging follow-up at 4 years but not due to ischemic driven. There was no scaffold thrombosis or TLF events through 4 years. Conclusions: Four years after the implantation, complete degradation and absorption of the Firsorb stent are evidenced in some patients. Firesorb stent is feasible and effective in the treatment of patients with non-complex coronary lesions. 目的: 报道置入生物可吸收支架Firesorb的患者术后4年的随访结果。 方法: 本研究为FUTURE I研究的4年随访结果。FUTURE I研究是一项评估Firesorb支架治疗冠状动脉狭窄病变的可行性、初步安全性和有效性的前瞻性、单中心、非盲法的首次人体试验。2016年1至3月在阜外医院入选原发、原位、单支、单处冠状动脉狭窄病变患者45例。成功置入Firesorb支架后,以2∶1比例随机分为队列1(n=30)和队列2(n=15)。队列1患者在支架置入术后6个月、2年时进行冠状动脉造影、血管内超声(IVUS)、光学相干断层成像(OCT)检查,队列2患者在术后1、3年时进行上述检查。所有纳入患者在支架置入术后1、6个月及1、2、3、4、5年时进行临床随访。研究主要终点为术后1个月靶病变失败(TLF,包括心原性死亡、靶血管心肌梗死、缺血驱动的靶病变血运重建),次要终点包括患者相关临床复合终点(PoCE,包括全因死亡、所有的心肌梗死、所有的血运重建事件)。 结果: 本研究共纳入45例成功置入Firesorb支架患者,年龄为(54.4±9.3)岁,其中男性35例(77.8%)。随访4年时队列1中10例患者复查了冠状动脉造影及OCT检查,其中2例患者置入的支架已经完全降解吸收,其他8例患者与队列2中患者3年时的OCT图像比较,支架降解程度增加,未见任何支架贴壁不良。4年临床随访率为100%。45例患者中有2例发生了PoCE事件(4.4%),其中1例患者术后第1 天发生了非靶血管心肌梗死、非靶血管血运重建,并且于术后2年再次发生靶血管非靶病变血运重建;另1例患者于复查冠状动脉造影时进行了非缺血驱动的靶病变血运重建。4年随访期间无TLF、明确或可能的支架内血栓事件。 结论: 在置入Firsorb支架术后4年时部分患者可出现支架的完全降解吸收。Firesorb支架治疗简单冠状动脉病变安全、有效。.
引用
- Li CJ, Xu B, Song L, et al. [The safety and efficacy of Firesorb bioresorbable scaffold in first-in-man study for coronary artery disease: the four-year outcomes]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 33611898. doi:10.3760/cma.j.cn112148-20201110-00897
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。